Literature DB >> 24266247

[Infectious mononucleosis--a "childhood disease" of great medical concern].

Ingo Stock1.   

Abstract

Infectious mononucleosis is usually a benign self-limiting disease, which is caused by the Epstein-Barr virus (EBV), a member of the Herpes virus family. EBV virions have a double-stranded, linear DNA genome surrounded by a protein capsid. EBV is transmitted primarily through saliva, but transmission via blood and droplets also occurs. Infectious mononucleosis is the most frequent clinical manifestation of EBV infection and occurs during primary infection with the virus. With some exceptions, only children older than 10 years, adolescents and young adults are suffering from the disease. Primary EBV infection in children up to 10 years is usually asymptomatic or shows unspecific courses. After an incubation period of up to seven weeks, a sore throat, mild fever and swollen lymph nodes in the neck area are the first signs of symptomatic infection. Further course of the disease often leads to hepatitis and swelling of the spleen. The symptoms usually subside after a few weeks, but protracted courses and clinical active infection also occur. The Epstein-Barr virus is distributed worldwide. At least 90% of all adults are seropositive to EBV. The treatment of infectious mononucleosis is mainly symptomatic, a generally effective specific therapy does not exist. A vaccine is currently not available.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24266247

Source DB:  PubMed          Journal:  Med Monatsschr Pharm        ISSN: 0342-9601


  2 in total

Review 1.  Human viruses and cancer.

Authors:  Abigail Morales-Sánchez; Ezequiel M Fuentes-Pananá
Journal:  Viruses       Date:  2014-10-23       Impact factor: 5.048

2.  TLR4 896A/G and TLR9 1174G/A polymorphisms are associated with the risk of infectious mononucleosis.

Authors:  Agnieszka Jabłońska; Mirosława Studzińska; Leszek Szenborn; Małgorzata Wiśniewska-Ligier; Monika Karlikowska-Skwarnik; Tomasz Gęsicki; Edyta Paradowska
Journal:  Sci Rep       Date:  2020-08-04       Impact factor: 4.379

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.